NC

Niranjana Chandappa Poojari

Active Director Director DIN 07742157
DIN 07742157 First appointment Feb 2017 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 3 historical roles
Total affiliations 6 Since Feb 2017
Shareholding value •••• Premium profile

About Niranjana Chandappa Poojari

Data last updated:

Niranjana Chandappa Poojari is a Director at Xenocor Pharmalab Private Limited (since 2022), Director at Avigna Learning Academy Private Limited (since 2021) and Director at East West Handling And Distribution Private Limited (since 2023). The companies operate in Pharma, Education & Learing and Other Industry. The 2 current companies with reported revenue have a combined latest revenue of ₹9.05 Cr; the largest is Xenocor Pharmalab Private Limited at ₹8.98 Cr (FY 2024). Earlier, Niranjana Chandappa Poojari was a Director at Stellence Pharmscience Private Limited (2017) and Director at Chiron Lifescience Private Limited (2017–2021) and 1 more.

DIN 07742157
Primary Designation Director
Industry Pharma
First Appointment 23 Feb 2017
Oldest Company Age 21 yrs
Largest company Xenocor Pharmalab Private Limited · ₹8.98 Cr (FY 2024)
Combined revenue ₹9.05 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Xenocor Pharmalab Private Limited U29299KA2007PTC042079
Director28 Mar 20222007₹8.98 Cr (FY 2024)Active
Director21 May 20212021₹7.4 Lakh (FY 2024)Active
Director30 May 20232005Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director01 Sep 20171992₹29.16 Cr (FY 2022)Under Cirp
Chiron Lifescience Private Limited U24239KA2017PTC100834
Director23 Feb 20172017Active
Designated Partner20 Oct 20202010₹32 Lakh (FY 2020)Converted To Cmp And Dissolved

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Avigna Learning Academy Llp
Xenocor Pharmalab Private Limited
Avigna Learning Academy Private Limited
East West Handling And Distribution Private Limited
Premium access

Shareholding and investment profile for Niranjana Chandappa Poojari

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Niranjana Chandappa Poojari

Niranjana Chandappa Poojari currently holds 3 directorships: Xenocor Pharmalab Private Limited (Director, since 28 Mar 2022, revenue ₹8.98 Cr (FY 2024)); Avigna Learning Academy Private Limited (Director, since 21 May 2021, revenue ₹7.4 Lakh (FY 2024)); East West Handling And Distribution Private Limited (Director, since 30 May 2023).

Niranjana Chandappa Poojari was first appointed on 23 Feb 2017 as Director at Chiron Lifescience Private Limited. The most recent appointment on record is 30 May 2023 at East West Handling And Distribution Private Limited.

The 2 current companies of Niranjana Chandappa Poojari that report revenue have a combined latest revenue of ₹9.05 Cr: Xenocor Pharmalab Private Limited ₹8.98 Cr (FY 2024); Avigna Learning Academy Private Limited ₹7.4 Lakh (FY 2024).

Niranjana Chandappa Poojari held 3 earlier board appointments: Stellence Pharmscience Private Limited (Director, 01 Sep 2017 to 21 Dec 2017); Chiron Lifescience Private Limited (Director, 23 Feb 2017 to 19 Jan 2021); Avigna Learning Academy Llp (Designated Partner, from 20 Oct 2020).

The current boards of Niranjana Chandappa Poojari's companies include Ranganathaiah Chetan (Xenocor Pharmalab Private Limited), Anuradha Ramachandran (Avigna Learning Academy Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available